VISK Viskase Holdings, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 727510 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY59.0%
TTM EPS YoY182.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-21.6%
ROA-8.2%
ROIC (approx.)-4.0%
Asset turnover—
Leverage & solvency
Liabilities / assets58.4%
Debt / equity1.52x
Current ratio1.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.44x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $26,000 | — | $26,000 | $701,000 |
| Operating income | -$5.31M | -$1.33M | -$1.04M | -$1.03M | -$469,000 |
| Pretax income | -$3.39M | $1.12M | $1.22M | -$386,000 | -$462,000 |
| Income tax | $19,000 | $347,000 | -$156,000 | -$200,000 | $7,000 |
| Net income | -$3.41M | $778,000 | $1.37M | -$186,000 | -$469,000 |
| EPS (basic) | -0.07 | -0.01 | 0.00 | -0.02 | -0.03 |
| EPS (diluted) | -0.07 | -0.01 | 0.00 | -0.02 | -0.03 |
| Weighted avg. shares (diluted) | 74.22M | 74.22M | 74.22M | 74.22M | 74,215 |
| Balance sheet | |||||
| Cash & equivalents | $9.22M | $5.70M | $47.01M | $46.98M | $47.64M |
| Receivables | $60.18M | — | — | — | — |
| Inventory | $96.75M | — | — | — | — |
| Current assets | $208.65M | $47.15M | $47.34M | $47.39M | $47.75M |
| PP&E, net | $141.30M | — | — | — | — |
| Goodwill | $3.13M | — | — | — | — |
| Intangibles | $13.40M | — | — | — | — |
| Total assets | $402.14M | $47.17M | $47.70M | $47.59M | $47.75M |
| Current liabilities | $214.52M | $1.68M | $1.71M | $1.70M | $403,000 |
| Short-term debt | $141.77M | — | — | — | — |
| Long-term debt | $141.77M | — | — | — | — |
| Total debt | $283.55M | — | — | — | — |
| Total liabilities | $257.78M | -$122.82M | $51.21M | $44.18M | $42.89M |
| Shareholders' equity | $145.84M | $3.01M | -$3.50M | $3.41M | $4.87M |
| Net debt | $274.33M | — | — | — | — |
| Shares outstanding | 6.61M | 74.21M | 74.21M | 74.21M | 74.21M |
| Cash flow statement | |||||
| Operating cash flow | -$3.01M | $1.12M | $1.30M | -$659,000 | -$501,000 |
| Financing cash flow | -$1.27M | -$1.27M | -$1.27M | — | $0 |
| Stock-based compensation | — | $0 | $0 | $0 | $0 |
| Dividends paid | $1.27M | $1.27M | $1.27M | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.